SILKROAD MEDICAL®

NOVEMBER 2020

Forward Looking Statement

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Silk Road's own internal estimates and research. While Silk Road believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources and undertakes no obligation to update such information after the date of this presentation. While Silk Road believes its internal research is reliable, such research has not been verified by any independent source.

This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, our future plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position, business strategy, current and prospective markets or products, clinical activities, regulatory approvals, degree of market acceptance, and plans and objectives of management for future operations, are forward-looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this presentation represent our views as of the date of this presentation. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors in our most recent 10-K filing and 10-Q filings made with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.



SILKROAD MEDICAL®

Establishing an **entirely new** minimally invasive procedure

Moving toward **standard of care** with growing clinical evidence base

for Stroke Prevention



Relentless Focus on Patient Outcomes Every patient. Every day.



2020 Strategic Priorities

U.S. TCAR Commercial Execution

- On track to end 2020 with 40-45 active territories
- Over 7,500 procedures have been performed through Q3 2020

2

Standard Surgical Risk

- Meaningful progress with FDA and other key stakeholders
- Details of strategy to be disclosed after YE 2020



Pipeline Development

- Product development efforts underway in acute ischemic stroke
- Expect neurovascular clinical and regulatory activities in 2021



Carotid Artery Disease –

33% of Ischemic Strokes

Cause of stroke:



Plaque fragments break off and move to brain


Prevalence

4.3M people in US have carotid stenosis



Source: Weerd M Stroke 2010; Modus Health Group 2018, Vascularweb.org

A ~\$2.6B Annual US Treatment Opportunity




Source: Modus Health Group data for 2017 and 2018; note: US opportunity calculated as procedure volume multiplied by average sales price of each TCAR product (1 unit each)

¹ Treated with CEA, CAS, or TCAR; does not include patients who undergo medical management alone; Includes both standard and high surgical risk

² Includes patients who did not undergo a surgical or endovascular procedure in 2018 and were instead monitored and treated with medical management alone




Unacceptable Treatment Options






The New Normal:



¹ Includes ~3% represented by TCAR procedures in 2018

TCAR is <u>the</u> Solution Paradigm Shift to Transcarotid



Ground-breaking innovations driving favorable patient outcomes and improved provider quality and economics

 $^{\rm 1}$ Reduction in In-Hospital and 30-Day Adverse Events $^{\rm 2}$ As compared to CEA



TCAR Carotid-Specific Design, Dedicated Portfolio

ENROUTE[®] Transcarotid Stent System Helps Protect the Brain After the Procedure ENHANCE[®] Transcarotid Peripheral Access Kit


ENPOUTE

ENROUTE[®] Transcarotid Neuroprotection System (NPS) *Helps Protect the Brain During the Procedure*

ENROUTE[®] 0.014" Guidewire




ENROUTE® Stent & Transcarotid Neuroprotection System in Action



Flow Controller with 200um filter



The proof is in the filter



25,000+ TCAR procedures worldwide¹


LOWN HIGH M

STOP



¹ Silk Road Medical Third Quarter 2020 Earnings Call on November 10, 2020

Growing Clinical Evidence 30 Day Stroke



Confirms Short Learning Curve

80% of enrolled physicians new to TCAR

Low Rates of 30-Day MAEs

Stroke/Death/MI (1.7%), Stroke/Death (0.8%), acute CNI (1.3%) and permanent CNI (0.5%)

Low 30-Day Stroke Rate in Vulnerable Sub-Groups

Symptomatic (0.6%), Female (0.5%) and Age>=75 (1.1%)

¹ N Engl J Med 2010; 363:11-23

² J Vasc Surg 2015;62:1227-35; ROADSTER outcomes presented on an "intention to treat" basis

³ Kashyap, Vikram. "Analysis of the Early Outcomes in the ROADSTER-2 Clinical Trial of Transcarotid Artery Revascularization in Patients with Significant Carotid Artery Disease". Presentation, Society for Vascular Surgery 2019 Vascular Annual Meeting, National Harbor, MD, June 15, 2019.

Note: ROADSTER2 data per FDA Analysis (Per Protocol)

13 Note: Major adverse events (MAEs); myocardial infarction (MI); cranial nerve injury (CNI)



TCAR Surveillance Project (TSP)

Trial Design and Purpose

- Ongoing, open-ended real-world surveillance
- High Surgical Risk patients
- Evaluate safety and effectiveness of TCAR vs. CEA (and CAS)
- Societal effort managed by SVS* and participating VQI* hospitals
- CMS coverage within the parameters of the existing NCD

Outcome Measures



In-hospital stroke, death, and stroke/death



Myocardial infarction and cranial nerve injury



One-year ipsilateral stroke or death




Procedure time; length of stay



TCAR Continues to Show Benefits over CEA

Results for 5,160 patients in each group¹ presented at VAM

In a matched population, TCAR shows...



¹ Malas, Mahmoud. "Outcomes of TransCarotid Artery Revascularization (TCAR) versus Carotid Endarterectomy (CEA) in the TCAR Surveillance Project." Presentation, Society for Vascular Surgery 2019 Vascular Annual Meeting, National Harbor, MD, June 13, 2019


² 30-day outcomes data based on a separate risk adjusted analysis

³ Outcomes data represent propensity score, in-hospital outcomes

Benefits of TCAR over CAS

Results for 3,286 TSP patients in each group¹ published in JAMA

In a matched population, TCAR shows...



¹ Marc L. Schermerhorn, MD, Patric Liang, MD, Jens Eldrup-Jorgensen, MD, et al. Revascularization vs Transfemoral Carotid Artery Stenting with Stroke or Death among Patients with Carotid Artery Stenosis. The Journal of the American Medical Association. 2019; 322(23):2313-2322. DOI: 10.1001/jama.2019.18441. Outcomes data represent propensity score outcomes. ² Technical failure defined as unable to access CCA, unable to cross carotid lesion, and unable to deploy stent



Easy-to-Learn Procedure with Many Physicians Trained

Decreasing operative time with No significant differences¹ in experience... major in-hospital outcomes were found regardless of experience 82 minutes level... **Stroke** 60 minutes Death **Composite stroke/death/MI** <5 cases >30 cases Novice Expert

Source: Kashyap, V.S., A.H. King et al. "Learning Curve for Surgeons Adopting Transcarotid Artery Revascularization Based on the Vascular Quality Initiative-Transcarotid Artery Revascularization Surveillance Project." *Journal of American College of Surgeons* (2019), doi: <u>https://doi.org/10.1016/j.jamcollsurg.2019.09.020</u>.

¹ Expert physicians were more likely to treat patients with moderate or severe congestive heart failure, novice and intermediate physicians were more likely to treat patients with prior CEA or CAS, and advanced and expert physicians were more likely to treat patients with CMS medical high-risk criteria.



TCAR: Established Codes and Payment

Physician: CPT Code				Hospital: ICD-10 Codes		
TCAR	37215	\$1,050		TCAR	DRGs 034-36	\$13,850
CEA	35301	\$1,187		CEA	DRGs 037-39	\$9 <i>,</i> 360
Pr Medicare nation	74 ROADSTER ¹ CEA: CR rocedure Time (minu	EST* Ites)			26% Lower odds of hospital stay >1 day ²	
*Standard Surgio ¹ J Vasc Surg 20 ² Malas, Mahmo	ical Risk patients (ROADSTER High St 015;62:1227-35; ROADSTER outcome oud. "Outcomes of TransCarotid Artery	urgical Risk) s presented on an "intention Revascularization (TCAR) ve	to treat" basis isus Carotid Endarterectomy (CEA) in the une 13, 2019. Outcomes data represent			SILI

MEDICAL®

Procedure Margin

Economic value proposition easily understood by Value Analysis Committees




Hospital stay margin: TCAR furthers the economic advantage by reducing in-hospital complications and length of stay

Source: Health Advances and company analysis ¹ Procedure costs include OR time, devices, medication, overhead, etc.




Commercial Strategy: Efficient Go-to-Market



¹ Data as of 12/31/18 (Source: Independent 3rd Party Market Data) ² Silk Road Medical Third Quarter 2020 Earnings Call on November 10, 2020






¹ Three months ended September 30, 2020

Growing TCAR Adoption


Utilization-Driven Revenue



¹ Second quarter revenue in 2020 included the recognition of \$1.3 million in deferred revenue due to a decrease in the provision for sales returns related to certain prior sales with a shorter shelf life, coupled with the downward trend in the company's historical returns rate



Solid Financial Profile




¹ Represents three-months ended September 30, 2020 compared to three-months ended September 30, 2019.


² Represents compound annual growth rate from twelve-months ended December 30, 2017 through December 30, 2019



Building and Maintaining a Sustainable Competitive Advantage









Built For Size and Scale

Proven Management Team



Med360, Visiogen, Boston Sci, Target



Andrew Davis	Chief Commercial Officer	Medtronic, Acelity, Boston Scientific		
Richard Ruedy	EVP Clinical, Reg, Quality	Abbott, Nevro, Edwards, Medtronic, Cardica, Acta		
Bill Whealon	EVP Research & Development	Medtronic, Covidien, ev3, Lake Region Manufacturing		
Alison Highlander	VP Human Resources	Roche, SRI, Atomic Tangerine		
Tammy Leitsinger	VP Med Affairs & Prof Education	Cordis, J&J		

SILKROAD MEDICAL®